Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


Articles published in Anticancer Res

Retrieve available abstracts of 109 articles:
HTML format
Text format



Single Articles


    June 2017
  1. FURRER D, Jacob S, Caron C, Sanschagrin F, et al
    Concordance of HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Using Tissue Microarray in Breast Cancer.
    Anticancer Res. 2017;37:3323-3329.
    PubMed     Text format     Abstract available


  2. STAMPFLI SF, Akhmedov A, Hausladen S, Varga Z, et al
    Tissue Factor Expression Does Not Predict Mortality in Breast Cancer Patients.
    Anticancer Res. 2017;37:3259-3264.
    PubMed     Text format     Abstract available


  3. BANYS-PALUCHOWSKI M, Witzel I, Riethdorf S, Rack B, et al
    Clinical Relevance of Serum HER2 and Circulating Tumor Cell Detection in Metastatic Breast Cancer Patients.
    Anticancer Res. 2017;37:3117-3128.
    PubMed     Text format     Abstract available


  4. GAVRESSEA T, Kalogeras KT, Koliou GA, Zagouri F, et al
    The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy.
    Anticancer Res. 2017;37:2947-2957.
    PubMed     Text format     Abstract available


  5. CHRISTOPOULOS PF, Papageorgiou E, Petraki C, Koutsilieris M, et al
    The COOH-terminus of the IGF-1Ec Isoform Enhances the Proliferation and Migration of Human MCF-7 Breast Cancer Cells.
    Anticancer Res. 2017;37:2899-2912.
    PubMed     Text format     Abstract available


  6. KUBAN-JANKOWSKA A, Gorska-Ponikowska M, Wozniak M
    Lipoic Acid Decreases the Viability of Breast Cancer Cells and Activity of PTP1B and SHP2.
    Anticancer Res. 2017;37:2893-2898.
    PubMed     Text format     Abstract available


    May 2017
  7. BYSTRICKY B, Cierna Z, Sieberova G, Janega P, et al
    Relationship Between Circulating Tumor Cells and Annexin A2 in Early Breast Cancer Patients.
    Anticancer Res. 2017;37:2727-2734.
    PubMed     Text format     Abstract available


  8. ESKELINEN M, Selander T, Ollonen P, Korhonen R, et al
    Moderate/severe Depression (MADRS) Can Affect the Quality of Life and Outcome Among Patients Admitted to Breast Cancer Diagnosis Unit.
    Anticancer Res. 2017;37:2641-2647.
    PubMed     Text format     Abstract available


  9. ANGELINI S, Botticelli A, Onesti CE, Giusti R, et al
    Pharmacogenetic Approach to Toxicity in Breast Cancer Patients Treated with Taxanes.
    Anticancer Res. 2017;37:2633-2639.
    PubMed     Text format     Abstract available


  10. MIYATA M, Ohguri T, Yahara K, Yamaguchi S, et al
    Salvage Radiotherapy for Solitary Metachronous Bone Metastasis in Patients with Breast Cancer.
    Anticancer Res. 2017;37:2575-2579.
    PubMed     Text format     Abstract available


  11. KHAN GN, Kim EJ, Shin TS, Lee SH, et al
    Azacytidine-induced Chemosensitivity to Doxorubicin in Human Breast Cancer MCF7 Cells.
    Anticancer Res. 2017;37:2355-2364.
    PubMed     Text format     Abstract available


  12. STRATI TM, Kotoula V, Kostopoulos I, Manousou K, et al
    Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer.
    Anticancer Res. 2017;37:2323-2334.
    PubMed     Text format     Abstract available


  13. JIANG XP, Elliott RL
    Decreased Iron in Cancer Cells and Their Microenvironment Improves Cytolysis of Breast Cancer Cells by Natural Killer Cells.
    Anticancer Res. 2017;37:2297-2305.
    PubMed     Text format     Abstract available


  14. DA CRUZ PAULA A, Lopes C
    Implications of Different Cancer Stem Cell Phenotypes in Breast Cancer.
    Anticancer Res. 2017;37:2173-2183.
    PubMed     Text format     Abstract available


    April 2017
  15. THANGARAJAH F, Enninga I, Malter W, Hamacher S, et al
    A Retrospective Analysis of Ki-67 Index and its Prognostic Significance in Over 800 Primary Breast Cancer Cases.
    Anticancer Res. 2017;37:1957-1964.
    PubMed     Text format     Abstract available


  16. INOUE Y, Yamashita N, Tokunaga E, Tanaka K, et al
    A Locally Advanced Breast Cancer that Achieved pCR with Pertuzumab, Trastuzumab and Docetaxel: Case Report.
    Anticancer Res. 2017;37:1917-1921.
    PubMed     Text format     Abstract available


  17. OKU Y, Nishiya N, Tsuda K, Shibazaki M, et al
    Dynamic Phenotypic Transition of Breast Cancer Cells In Vitro Revealed by Self-floating Cell Culture.
    Anticancer Res. 2017;37:1793-1797.
    PubMed     Text format     Abstract available


  18. BYSTRICKY B, Jurisova S, Karaba M, Minarik G, et al
    Relationship Between Circulating Tumor Cells and Tissue Plasminogen Activator in Patients with Early Breast Cancer.
    Anticancer Res. 2017;37:1787-1791.
    PubMed     Text format     Abstract available


  19. KIM KY, Park KI, Kim SH, Yu SN, et al
    Salinomycin Induces Reactive Oxygen Species and Apoptosis in Aggressive Breast Cancer Cells as Mediated with Regulation of Autophagy.
    Anticancer Res. 2017;37:1747-1758.
    PubMed     Text format     Abstract available


  20. DAS T, Nair RR, Green R, Padhee S, et al
    Actinomycin D Down-regulates SOX2 Expression and Induces Death in Breast Cancer Stem Cells.
    Anticancer Res. 2017;37:1655-1663.
    PubMed     Text format     Abstract available


  21. ACUNA UM, Curley RW Jr, Fatima N, Ahmed S, et al
    Differential Effect of Wortmannolone Derivatives on MDA-MB-231 Breast Cancer Cells.
    Anticancer Res. 2017;37:1617-1623.
    PubMed     Text format     Abstract available


  22. JELINEK M, Kabelova A, Sramek J, Seitz J, et al
    Differing Mechanisms of Death Induction by Fluorinated Taxane SB-T-12854 in Breast Cancer Cells.
    Anticancer Res. 2017;37:1581-1590.
    PubMed     Text format     Abstract available


  23. CHIRICO A, Serpentini S, Merluzzi T, Mallia L, et al
    Self-efficacy for Coping Moderates the Effects of Distress on Quality of Life in Palliative Cancer Care.
    Anticancer Res. 2017;37:1609-1615.
    PubMed     Text format     Abstract available


  24. KAISER CG, Herold M, Krammer J, Baltzer P, et al
    Prognostic Value of "Prepectoral Edema" in MR-mammography.
    Anticancer Res. 2017;37:1989-1995.
    PubMed     Text format     Abstract available


  25. VOGL UM, Ohler L, Rasic M, Frischer JM, et al
    Evaluation of Prognostic Immune Signatures in Patients with Breast, Colorectal and Pancreatic Cancer Receiving Chemotherapy.
    Anticancer Res. 2017;37:1947-1955.
    PubMed     Text format     Abstract available


    March 2017
  26. KIM HA, Kim JH, Choi HS, Kim YG, et al
    Core Needle Biopsy Specimens Are More Appropriate than Surgical Specimens for Evaluating the Expression of Phosphoproteins as Biological Markers in Invasive Breast Cancer.
    Anticancer Res. 2017;37:1409-1412.
    PubMed     Text format     Abstract available


  27. DIERAS V, Pop S, Berger F, Dujaric ME, et al
    First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study.
    Anticancer Res. 2017;37:1403-1407.
    PubMed     Text format     Abstract available


  28. WENDT C, Lindblom A, Arver B, VON Wachenfeldt A, et al
    Parent of Origin and Prognosis in Familial Breast Cancer in Sweden.
    Anticancer Res. 2017;37:1257-1262.
    PubMed     Text format     Abstract available


  29. MACK N, Mazzio EA, Bauer D, Flores-Rozas H, et al
    Stable shRNA Silencing of Lactate Dehydrogenase A (LDHA) in Human MDA-MB-231 Breast Cancer Cells Fails to Alter Lactic Acid Production, Glycolytic Activity, ATP or Survival.
    Anticancer Res. 2017;37:1205-1212.
    PubMed     Text format     Abstract available


  30. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    MIC1/GDF15 as a Bone Metastatic Disease Biomarker.
    Anticancer Res. 2017;37:1501-1505.
    PubMed     Text format     Abstract available


  31. SEKIDO Y, Ohigashi S, Takahashi T, Hayashi N, et al
    Familial Gastrointestinal Stromal Tumor with Germline KIT Mutations Accompanying Hereditary Breast and Ovarian Cancer Syndrome.
    Anticancer Res. 2017;37:1425-1431.
    PubMed     Text format     Abstract available


  32. IIZUKA D, Sasatani M, Barcellos-Hoff MH, Kamiya K, et al
    Hydrogen Peroxide Enhances TGFbeta-mediated Epithelial-to-Mesenchymal Transition in Human Mammary Epithelial MCF-10A Cells.
    Anticancer Res. 2017;37:987-995.
    PubMed     Text format     Abstract available


    February 2017
  33. ILENKO A, Sergent F, Mercuzot A, Zitoun M, et al
    Could Patients Older than 75 Years Benefit from a Systematic Breast Cancer Screening Program?
    Anticancer Res. 2017;37:903-907.
    PubMed     Text format     Abstract available


  34. LAWLER G, Leech M
    Dose Sparing Potential of Deep Inspiration Breath-hold Technique for Left Breast Cancer Radiotherapy Organs-at-risk.
    Anticancer Res. 2017;37:883-890.
    PubMed     Text format     Abstract available


  35. ESKELINEN M, Korhonen R, Selander T, Ollonen P, et al
    Beck Depression Inventory as a Predictor of Long-term Outcome Among Patients Admitted to the Breast Cancer Diagnosis Unit: A 25-year Cohort Study in Finland.
    Anticancer Res. 2017;37:819-824.
    PubMed     Text format     Abstract available


  36. WU HC, Southey MC, Hibshoosh H, Santella RM, et al
    DNA Methylation in Breast Tumor from High-risk Women in the Breast Cancer Family Registry.
    Anticancer Res. 2017;37:659-664.
    PubMed     Text format     Abstract available


  37. ONISHI H, Suyama K, Yamasaki A, Oyama Y, et al
    CD24 Modulates Chemosensitivity of MCF-7 Breast Cancer Cells.
    Anticancer Res. 2017;37:561-565.
    PubMed     Text format     Abstract available


    January 2017

  38. Radiation Therapy Techniques and Treatment Planning for Breast Cancer.
    Anticancer Res. 2017;37:369-370.
    PubMed     Text format    



  39. The Pathobiology of Breast Cancer.
    Anticancer Res. 2017;37:365.
    PubMed     Text format    


  40. YANG X, DU G, Yu Z, Si Y, et al
    A Novel NHERF1 Mutation in Human Breast Cancer and Effects on Malignant Progression.
    Anticancer Res. 2017;37:67-73.
    PubMed     Text format     Abstract available


  41. YANO S, Takehara K, Kishimoto H, Tazawa H, et al
    Comparison of Tumor Recurrence After Resection of Highly- and Poorly-Metastatic Triple-negative Breast Cancer in Orthotopic Nude-Mouse Models.
    Anticancer Res. 2017;37:57-60.
    PubMed     Text format     Abstract available


  42. DAMASKOS C, Valsami S, Kontos M, Spartalis E, et al
    Histone Deacetylase Inhibitors: An Attractive Therapeutic Strategy Against Breast Cancer.
    Anticancer Res. 2017;37:35-46.
    PubMed     Text format     Abstract available


  43. STRIEN L, Joensuu K, Heikkila P, Leidenius MH, et al
    Different Expression Patterns of CXCR4, CCR7, Maspin and FOXP3 in Luminal Breast Cancers and Their Sentinel Node Metastases.
    Anticancer Res. 2017;37:175-182.
    PubMed     Text format     Abstract available


  44. GIPPONI M, Baldelli I, Atzori G, Fregatti P, et al
    Tumescent Anesthesia in Skin- and Nipple-sparing Mastectomy: Results of a Prospective Clinical Study.
    Anticancer Res. 2017;37:349-352.
    PubMed     Text format     Abstract available


  45. SCHRODER L, Koch J, Mahner S, Kost BP, et al
    The Effects of Petroselinum Crispum on Estrogen Receptor-positive Benign and Malignant Mammary Cells (MCF12A/MCF7).
    Anticancer Res. 2017;37:95-102.
    PubMed     Text format     Abstract available


    December 2016
  46. RAY A, Khong B, Khong HT
    A Case Report of Pneumocystis Jiroveci Pneumonia in a Patient with Metastatic Breast Cancer.
    Anticancer Res. 2016;36:6673-6676.
    PubMed     Text format     Abstract available


  47. LUKESOVA L, Vrana D, Svach I, Zlamalova N, et al
    Prognostic Influence of Internal Mammary Node Drainage in Patients with Early-stage Breast Cancer.
    Anticancer Res. 2016;36:6641-6646.
    PubMed     Text format     Abstract available


  48. SAKAGUCHI K, Nakatsukasa K, Taguchi T
    Phase I Study of Triweekly Nab-Paclitaxel Combined with S-1 in Patients with HER2-negative Metastatic Breast Cancer.
    Anticancer Res. 2016;36:6515-6519.
    PubMed     Text format     Abstract available


  49. TANAKA S, Iwamoto M, Kimura K, Takahashi Y, et al
    A Phase II Study of Adjuvant Chemotherapy of Tegafur-Uracil for Patients with Breast Cancer with HER2-negative Pathologic Residual Invasive Disease After Neoadjuvant Chemotherapy.
    Anticancer Res. 2016;36:6505-6509.
    PubMed     Text format     Abstract available


  50. TIAINEN L, Tanner M, Lahdenpera O, Vihinen P, et al
    Bevacizumab Combined with Docetaxel or Paclitaxel as First-line Treatment of HER2-negative Metastatic Breast Cancer.
    Anticancer Res. 2016;36:6431-6438.
    PubMed     Text format     Abstract available


  51. RAMDANI LH, Talhi O, Taibi N, Delort L, et al
    Effects of Spiro-bisheterocycles on Proliferation and Apoptosis in Human Breast Cancer Cell Lines.
    Anticancer Res. 2016;36:6399-6408.
    PubMed     Text format     Abstract available


  52. LEE J, Jung JH, Chae YS, Park HY, et al
    Long Noncoding RNA snaR Regulates Proliferation, Migration and Invasion of Triple-negative Breast Cancer Cells.
    Anticancer Res. 2016;36:6289-6295.
    PubMed     Text format     Abstract available


  53. YANO S, Takehara K, Kishimoto H, Tazawa H, et al
    In Vivo Selection of Intermediately- and Highly-Malignant Variants of Triple-negative Breast Cancer in Orthotopic Nude Mouse Models.
    Anticancer Res. 2016;36:6273-6277.
    PubMed     Text format     Abstract available


    November 2016
  54. SHINDEN Y, Kijima Y, Hirata M, Arima H, et al
    Clinical Significance of the Histoculture Drug Response Assay in Breast Cancer.
    Anticancer Res. 2016;36:6173-6178.
    PubMed     Text format     Abstract available


  55. LEE SJ, Park BN, Roh JH, An YS, et al
    Enhancing the Therapeutic Efficacy of 2-Deoxyglucose in Breast Cancer Cells Using Cell-cycle Synchronization.
    Anticancer Res. 2016;36:5975-5980.
    PubMed     Text format     Abstract available


  56. PIRES BR, DE Amorim IS, Souza LD, Rodrigues JA, et al
    Targeting Cellular Signaling Pathways in Breast Cancer Stem Cells and its Implication for Cancer Treatment.
    Anticancer Res. 2016;36:5681-5691.
    PubMed     Text format     Abstract available


  57. VOUTSADAKIS IA
    Immune Blockade Inhibition in Breast Cancer.
    Anticancer Res. 2016;36:5607-5622.
    PubMed     Text format     Abstract available


    October 2016
  58. WALDREP AR, Avery EJ, Rose FF Jr, Midathada MV, et al
    Breast Cancer Subtype Influences the Accuracy of Predicting Pathologic Response by Imaging and Clinical Breast Exam After Neoadjuvant Chemotherapy.
    Anticancer Res. 2016;36:5389-5395.
    PubMed     Text format     Abstract available


  59. QIN W, Holick MF, Sorensen W, Walker CR, et al
    Vitamin D3 Treatment Influences PGE2 and TGFbeta in Normal and Increased Breast Cancer Risk Women.
    Anticancer Res. 2016;36:5347-5353.
    PubMed     Text format     Abstract available


  60. VILSMAIER T, Rack B, Konig A, Friese K, et al
    Influence of Circulating Tumour Cells on Production of IL-1alpha, IL-1beta and IL-12 in Sera of Patients with Primary Diagnosis of Breast Cancer Before Treatment.
    Anticancer Res. 2016;36:5227-5236.
    PubMed     Text format     Abstract available


  61. TAKEDA S, Okazaki H, Kudo T, Kakizoe K, et al
    Bongkrekic Acid as a Warburg Effect Modulator in Long-term Estradiol-deprived MCF-7 Breast Cancer Cells.
    Anticancer Res. 2016;36:5171-5182.
    PubMed     Text format     Abstract available


  62. GANGAPURAM M, Jean R, Mazzio E, Badisa R, et al
    Substituted Tetrahydroisoquinolines as Microtubule-destabilizing Agents in Triple Negative Human Breast Cancer Cells.
    Anticancer Res. 2016;36:5043-5052.
    PubMed     Text format     Abstract available


  63. SHAVERDIAN N, Wang J, Levin-Epstein R, Schaue D, et al
    Pro-inflammatory State Portends Poor Outcomes with Stereotactic Radiosurgery for Brain Metastases.
    Anticancer Res. 2016;36:5333-5337.
    PubMed     Text format     Abstract available


  64. STAHL JM, Hong JC, Lester-Coll NH, Kann BH, et al
    Chest Wall Deformity in the Radiation Oncology Clinic.
    Anticancer Res. 2016;36:5295-5300.
    PubMed     Text format     Abstract available


  65. FUJII T, Yajima R, Kurozumi S, Higuchi T, et al
    Clinical Significance of 18F-FDG-PET in Invasive Lobular Carcinoma.
    Anticancer Res. 2016;36:5481-5485.
    PubMed     Text format     Abstract available


    September 2016
  66. RIOS N, Adaskina N, Fromke C, Papendorf F, et al
    The Benefit of Baseline Staging-Risk Assessment of Distant Breast Cancer Metastases by Tumor Stage.
    Anticancer Res. 2016;36:4909-14.
    PubMed     Text format     Abstract available


  67. KIM YJ, Kim K, Lee R, Kim J, et al
    Two-year Follow-up of Volumetric-modulated Arc Therapy for Treating Internal Mammary Nodes in Locally Advanced Breast Cancer.
    Anticancer Res. 2016;36:4847-51.
    PubMed     Text format     Abstract available


  68. HEPP P, Andergassen U, Jager B, Trapp E, et al
    Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
    Anticancer Res. 2016;36:4771-6.
    PubMed     Text format     Abstract available


  69. FURRER D, Jacob S, Caron C, Sanschagrin F, et al
    Tissue Microarray Is a Reliable Tool for the Evaluation of HER2 Amplification in Breast Cancer.
    Anticancer Res. 2016;36:4661-6.
    PubMed     Text format     Abstract available


  70. WAZIR U, El Hage Chehade H, Headon H, Oteifa M, et al
    Oncological Safety of Lipofilling in Patients with Breast Cancer: A Meta-analysis and Update on Clinical Practice.
    Anticancer Res. 2016;36:4521-8.
    PubMed     Text format     Abstract available


  71. KAPPIL M, Terry MB, Delgado-Cruzata L, Liao Y, et al
    Mismatch Repair Polymorphisms as Markers of Breast Cancer Prevalence in the Breast Cancer Family Registry.
    Anticancer Res. 2016;36:4437-41.
    PubMed     Text format     Abstract available


  72. DO SI, Yoon G, Kim HS, Kim K, et al
    Increased Brahma-related Gene 1 Expression Predicts Distant Metastasis and Shorter Survival in Patients with Invasive Ductal Carcinoma of the Breast.
    Anticancer Res. 2016;36:4873-82.
    PubMed     Text format     Abstract available


    August 2016

  73. Handbook of HER2-Targeted Agents in Breast Cancer.
    Anticancer Res. 2016;36:4377.
    PubMed     Text format    


  74. KARLIKOVA M, Topolcan O, Narsanska A, Kucera R, et al
    Circulating Growth and Angiogenic Factors and Lymph Node Status in Early-stage Breast Cancer - A Pilot Study.
    Anticancer Res. 2016;36:4209-14.
    PubMed     Text format     Abstract available


  75. PIMENTEL C, Becquet M, Lavoue V, Henno S, et al
    Ovarian Metastases from Breast Cancer: A Series of 28 Cases.
    Anticancer Res. 2016;36:4195-200.
    PubMed     Text format     Abstract available


  76. KAPPIL MA, Liao Y, Terry MB, Santella RM, et al
    DNA Repair Gene Expression Levels as Indicators of Breast Cancer in the Breast Cancer Family Registry.
    Anticancer Res. 2016;36:4039-44.
    PubMed     Text format     Abstract available


  77. CHIANG KC, Hsu SY, Lin SJ, Yeh CN, et al
    PTEN Insufficiency Increases Breast Cancer Cell Metastasis In Vitro and In Vivo in a Xenograft Zebrafish Model.
    Anticancer Res. 2016;36:3997-4005.
    PubMed     Text format     Abstract available


  78. FULAWKA L, Halon A
    Proliferation Index Evaluation in Breast Cancer Using ImageJ and ImmunoRatio Applications.
    Anticancer Res. 2016;36:3965-72.
    PubMed     Text format     Abstract available


  79. HOWARD CB, McDowell R, Feleke K, Deer E, et al
    Chemotherapeutic Vulnerability of Triple-negative Breast Cancer Cell-derived Tumors to Pretreatment with Vernonia amygdalina Aqueous Extracts.
    Anticancer Res. 2016;36:3933-43.
    PubMed     Text format     Abstract available


  80. BENDRAT K, Fritz P, Muller S, Brockmoller S, et al
    Improved Risk Stratification for Breast Cancer Samples Based on the Expression Ratio of the Estrogen and Progesterone Receptor.
    Anticancer Res. 2016;36:3855-63.
    PubMed     Text format     Abstract available


  81. YANO S, Takehara K, Miwa S, Kishimoto H, et al
    In Vivo Isolation of a Highly-aggressive Variant of Triple-negative Human Breast Cancer MDA-MB-231 Using Serial Orthotopic Transplantation.
    Anticancer Res. 2016;36:3817-20.
    PubMed     Text format     Abstract available



  82. Breast Disease. Management and Therapies.
    Anticancer Res. 2016;36:4376.
    PubMed     Text format    


  83. LUCZYNSKA E, Heinze S, Adamczyk A, Rys J, et al
    Comparison of the Mammography, Contrast-Enhanced Spectral Mammography and Ultrasonography in a Group of 116 patients.
    Anticancer Res. 2016;36:4359-66.
    PubMed     Text format     Abstract available


  84. FUJII T, Yajima R, Kuwano H
    Implications of Long-term Indwelling of Tissue Expander in Breast Reconstruction: Risk of Expander Rupturing.
    Anticancer Res. 2016;36:4337-40.
    PubMed     Text format     Abstract available


    July 2016
  85. NAM SO, Yotsumoto F, Miyata K, Fukagawa S, et al
    Anti-tumor Effect of Intravenous Administration of CRM197 for Triple-negative Breast Cancer Therapy.
    Anticancer Res. 2016;36:3651-7.
    PubMed     Text format     Abstract available


  86. SHIMAMURA Y, Tamatani D, Kuniyasu S, Mizuki Y, et al
    5-Aminolevulinic Acid Enhances Ultrasound-mediated Antitumor Activity via Mitochondrial Oxidative Damage in Breast Cancer.
    Anticancer Res. 2016;36:3607-12.
    PubMed     Text format     Abstract available


  87. CRISCITIELLO C, Bagnardi V, Viale G, Disalvatore D, et al
    HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence.
    Anticancer Res. 2016;36:3537-40.
    PubMed     Text format     Abstract available


  88. SU CH, Lane HY, Hsiao CL, Liu LC, et al
    Matrix Metalloproteinase-1 Genetic Polymorphism in Breast Cancer in Taiwanese.
    Anticancer Res. 2016;36:3341-3345.
    PubMed     Text format     Abstract available


  89. SAMARA P, Skopeliti M, Tsiatas ML, Georgaki S, et al
    A Cytokine Cocktail Augments the Efficacy of Adoptive NK-92 Cell Therapy Against Mouse Xenografts of Human Cancer.
    Anticancer Res. 2016;36:3373-82.
    PubMed     Text format     Abstract available


    June 2016

  90. Novel Biomarkers in the Continuum of Breast Cancer.
    Anticancer Res. 2016;36:3224.
    PubMed     Text format    


  91. ANDERGASSEN U, Vogl A, Mumm JN, Kolbl AC, et al
    Immunocytochemical Characterization of Disseminated Tumour Cells from Bone Marrow of Breast Cancer Patients.
    Anticancer Res. 2016;36:3217-22.
    PubMed     Text format     Abstract available


  92. KOLBL AC, Brauer D, Hutter S, Rack B, et al
    New Marker Genes for Real-Time PCR-based Detection of Circulating Tumour Cells from Blood of Breast Cancer Patients.
    Anticancer Res. 2016;36:3211-6.
    PubMed     Text format     Abstract available


  93. KOLBEN T, Hary T, Holdt LM, Schwarz TM, et al
    Thyroid Hormones and Vitamin D in Patients with Breast Cancer with Mutations in BRCA1 or BRCA2 Genes.
    Anticancer Res. 2016;36:3185-90.
    PubMed     Text format     Abstract available


  94. FREIER CP, Kuhn C, Endres S, Mayr D, et al
    FOXP3+ Cells Recruited by CCL22 into Breast Cancer Correlates with Less Tumor Nodal Infiltration.
    Anticancer Res. 2016;36:3139-45.
    PubMed     Text format     Abstract available


  95. KONIG A, Vilsmaier T, Rack B, Friese K, et al
    Determination of Interleukin-4, -5, -6, -8 and -13 in Serum of Patients with Breast Cancer Before Treatment and its Correlation to Circulating Tumor Cells.
    Anticancer Res. 2016;36:3123-30.
    PubMed     Text format     Abstract available


  96. FUJII T, Yajima R, Tsuboi M, Higuchi T, et al
    Clinicopathological Features of Cases with Primary Breast Cancer not Identified by 18F-FDG-PET.
    Anticancer Res. 2016;36:3019-22.
    PubMed     Text format     Abstract available


  97. SHIMA H, Kutomi G, Satomi F, Maeda H, et al
    SOX2 and ALDH1 as Predictors of Operable Breast Cancer.
    Anticancer Res. 2016;36:2945-53.
    PubMed     Text format     Abstract available


  98. BRAUTIGAM K, Mitzlaff K, Uebel L, Koster F, et al
    Subtypes of Triple-negative Breast Cancer Cell Lines React Differently to Eribulin Mesylate.
    Anticancer Res. 2016;36:2759-66.
    PubMed     Text format     Abstract available


  99. SCHELZ Z, Ocsovszki I, Bozsity N, Hohmann J, et al
    Antiproliferative Effects of Various Furanoacridones Isolated from Ruta graveolens on Human Breast Cancer Cell Lines.
    Anticancer Res. 2016;36:2751-8.
    PubMed     Text format     Abstract available


  100. KASSAYOVA M, Bobrov N, Strojny L, Orendas P, et al
    Anticancer and Immunomodulatory Effects of Lactobacillus plantarum LS/07, Inulin and Melatonin in NMU-induced Rat Model of Breast Cancer.
    Anticancer Res. 2016;36:2719-28.
    PubMed     Text format     Abstract available


  101. KIM JY, Heo SH, Song IH, Park IA, et al
    Activation of the PERK-eIF2alpha Pathway Is Associated with Tumor-infiltrating Lymphocytes in HER2-Positive Breast Cancer.
    Anticancer Res. 2016;36:2705-11.
    PubMed     Text format     Abstract available


  102. MIN DJ, He S, Green JE
    Birinapant (TL32711) Improves Responses to GEM/AZD7762 Combination Therapy in Triple-negative Breast Cancer Cell Lines.
    Anticancer Res. 2016;36:2649-57.
    PubMed     Text format     Abstract available


    April 2016
  103. WINDRICHOVA J, Fuchsova R, Kucera R, Topolcan O, et al
    Testing of a Novel Cancer Metastatic Multiplex Panel for the Detection of Bone-metastatic Disease - a Pilot Study.
    Anticancer Res. 2016;36:1973-8.
    PubMed     Text format     Abstract available


  104. RAPOSO TP, Beirao BC, Pires I, Prada J, et al
    Immunohistochemical Expression of CCR2, CSF1R and MMP9 in Canine Inflammatory Mammary Carcinomas.
    Anticancer Res. 2016;36:1805-13.
    PubMed     Text format     Abstract available


  105. MOSS T, Chirico A, Mallia L, Lucidi F, et al
    Psychosocial Outcomes of Quadrantectomy Versus Mastectomy in a Southern Italian Sample: Development and Needs of the Italian Derriford Appearance Scale 24.
    Anticancer Res. 2016;36:1519-26.
    PubMed     Text format     Abstract available


    March 2016
  106. CUI YX, Evans BA, Jiang WG
    New Roles of Osteocytes in Proliferation, Migration and Invasion of Breast and Prostate Cancer Cells.
    Anticancer Res. 2016;36:1193-201.
    PubMed     Text format     Abstract available


    February 2016
  107. AMABILE MI, Monti M, Merola R, Frusone F, et al
    Nipple-sparing Mastectomy in Patients with Preoperative Diagnosis of Non-invasive Breast Carcinoma. A Single-center Experience.
    Anticancer Res. 2016;36:779-83.
    PubMed     Text format     Abstract available


  108. KUCERA R, Topolcan O, Fiala O, Kinkorova J, et al
    The Role of TPS and TPA in the Diagnostics of Distant Metastases.
    Anticancer Res. 2016;36:773-7.
    PubMed     Text format     Abstract available


    January 2016
  109. GITT A, Bose-Ribeiro H, Nieder C, Kup PG, et al
    Treatment Results of MammoSite Catheter in Combination with Whole-breast Irradiation.
    Anticancer Res. 2016;36:355-60.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: